Allarity Therapeutics(ALLR)

Focus: Allarity Therapeutics is a Boston-based oncology-focused biotech company specializing in cancer treatments paired with companion diagnostics. The company is publicly traded (NASDAQ: ALLR) with a clinical-stage pipeline in early-to-mid development phases.

Oncology

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Allarity Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Allarity Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

FY2025

Pipeline & Clinical Trials

Drug Response Predictor

Ovarian Cancer

N/A

Clinical Trials (1)

NCT03877796Clinical Pre-screening Protocol for Ovarian Cancer

N/A

Help build intelligence for Allarity Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on precision oncology with integrated diagnostic approaches across multiple solid tumors and hematologic malignancies
Public company status provides liquidity and potential equity upside with clinical catalysts ahead across Phase 1/2 and Phase 2 programs
Focused pipeline with 6 active programs allows meaningful individual impact on oncology drug development

Watch Out For

Severely constrained cash position ($20M in FY2025) with significant operating losses ($24.5M in FY2025) limits hiring and career growth opportunities
Zero open job requisitions and declining R&D spend ($6M in FY2025 vs $7M in FY2024) suggest potential workforce contraction or hiring freeze
No Phase 3 programs in pipeline and minimal clinical trial activity (7 trials total) creates limited near-term catalysts or milestone visibility

Generated by Claude from Allarity Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

APO010

Relapsed/Refractory Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT03196947Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

Phase 1/2

LiPlaCis

Advanced or Refractory Solid Tumours

Phase 1/2

Clinical Trials (1)

NCT01861496Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

Phase 1/2

2X-121

Metastatic Breast Cancer

Phase 2

Clinical Trials (3)

NCT03878849Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

Phase 2

NCT03562832Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Phase 2

NCT05571969Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Phase 1

Ixabepilone

Metastatic Breast Cancer

Phase 2

Clinical Trials (1)

NCT04796324Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Phase 2

Irofulven

Metastatic Castration-Resistant Prostate Cancer

Phase 2

Clinical Trials (1)

NCT03643107Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

8 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

R&D Spend

$6M14%

Net Income

-$25M

Cash